Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
OBJECTIVE
Anterior chamber involvement is unusual in patients with acute lymphoblastic leukemia (ALL) and has never been described in the setting of Ph+ (Philadelphia chromosome-positive) ALL. Moreover, there have been no reports of this complication as a primary relapse in a patient treated with imatinib.


METHODS
Interventional case report.


METHODS
A 55-year-old woman with Ph+ ALL in complete remission with imatinib and presenting unilateral anterior uveitis at initial examination was clinically evaluated. Hematologic and ocular studies were performed: blood films, bone marrow smears, and anterior chamber paracentesis with aqueous fluid cytology.


RESULTS
Although there was no evidence of leukemia in the blood or bone marrow samples, aqueous fluid cytology identified Ph+ positive lymphoblastic leukemic cells.


CONCLUSIONS
The patient had developed anterior chamber infiltration without hematological relapse while treated with imatinib. In our opinion, paracentesis should be performed without delay when uveitis develops in ALL, regardless of systemic relapse.
Hurtado-Sarrió
Mercedes
M
Ophthalmology Service, La Fe Hospital, Valencia, Spain. hurtado_mer@gva.es
Duch-Samper
Antonio
A
Taboada-Esteve
Juan
J
Martínez-Dominguez
Jesús A
JA
Senent-Peris
M Leonor
ML
Menezo-Rozalén
Jose L
JL
D000867:Anterior Chamber / Q000473:pathology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000166:cytology; D001549:Benzamides; D005134:Eye Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D017254:Leukemic Infiltration / Q000473:pathology*; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D014606:Uveitis, Anterior / Q000175:diagnosis
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate